Eisai announced that the FDA has approved Aciphex Sprinkle (rabeprazole sodium) Delayed-Release Capsules for the treatment of gastroesophageal reflux disease (GERD) in children 1–11 years of age for ...

Aciphex is a proton-pump inhibitor that works by decreasing the amount of acid made in the stomach to treat the symptoms of GERD (eg, heartburn, regurgitation of acid, and nausea). Aciphex is also ...

March 13, 2007 — The US Food and Drug Administration (FDA) has approved first-time generic formulations for rabeprazole sodium 20-mg delayed-release tablets and ranitidine HCl 15-mg/mL oral ...

HealthDay News — The FDA has approved the first generic versions of the gastroesophageal reflux disease (GERD) drug Aciphex (rabeprazole sodium) for people aged 12 and older, the agency has announced.

WOODCLIFF LAKE, N.J., Nov. 30, 2012 /PRNewswire/ -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review Eisai's New Drug Application (NDA) for ...

The US Food and Drug Administration (FDA) has approved the first generic versions of Aciphex (rabeprazole sodium; Eisai) delayed-release tablets for the treatment of gastroesophageal reflux disease ...

Japan’s Eisai says that US regulators have granted a priority review for a new application of the firm’s proton pump inhibitor Aciphex. Japan’s Eisai says that US regulators have granted a priority ...

WOODCLIFF LAKE, N.J. The Food and Drug Administration has approved Aciphex for treatment of gastroesophageal reflux disease in adolescents age 12 and older, Tokyo-based Eisai’s North America ...

NEW YORK, May 11 (Reuters) - A U.S. court on Friday upheld drug companies seeking to sell cheap versions of the medicine. The court decision was a major victory for Japan-based Eisai, which derives ...

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced today that the company has decided to terminate development of its investigational proton pump inhibitor (PPI), ...

Eisai has decided to discontinue development of an extended-release version of proton pump inhibitor Aciphex/Pariet. Eisai has decided to discontinue development of an extended-release version of ...